These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15078175)

  • 1. Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.
    Hamer DH
    Curr HIV Res; 2004 Apr; 2(2):99-111. PubMed ID: 15078175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which therapeutic strategy will achieve a cure for HIV-1?
    Cillo AR; Mellors JW
    Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Block-And-Lock: New Horizons for a Cure for HIV-1.
    Moranguinho I; Valente ST
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33334019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of HIV in infected patients: some potential approaches.
    Yang QE
    Med Sci Monit; 2004 Jul; 10(7):RA155-65. PubMed ID: 15232518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reservoirs of HIV replication after successful combined antiretroviral treatment.
    Belmonte L; Baré P; de Bracco MM; Ruibal-Ares BH
    Curr Med Chem; 2003 Feb; 10(4):303-12. PubMed ID: 12570703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Between a shock and a hard place: challenges and developments in HIV latency reversal.
    Zerbato JM; Purves HV; Lewin SR; Rasmussen TA
    Curr Opin Virol; 2019 Oct; 38():1-9. PubMed ID: 31048093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and strategies for the eradication of the HIV reservoir.
    Kimata JT; Rice AP; Wang J
    Curr Opin Immunol; 2016 Oct; 42():65-70. PubMed ID: 27288651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
    Sedaghat AR; Siliciano JD; Brennan TP; Wilke CO; Siliciano RF
    PLoS Pathog; 2007 Aug; 3(8):e122. PubMed ID: 17784786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peering into the HIV reservoir.
    García M; Buzón MJ; Benito JM; Rallón N
    Rev Med Virol; 2018 Jul; 28(4):e1981. PubMed ID: 29744964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kill: boosting HIV-specific immune responses.
    Trautmann L
    Curr Opin HIV AIDS; 2016 Jul; 11(4):409-16. PubMed ID: 27054280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of viral reservoirs in HIV-1 infection.
    Blankson JN; Persaud D; Siliciano RF
    Annu Rev Med; 2002; 53():557-93. PubMed ID: 11818490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV may be cured].
    Kjær AS; Østergaard HB
    Ugeskr Laeger; 2015 Apr; 177(17):. PubMed ID: 25922162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle-Based Immunoengineered Approaches for Combating HIV.
    Bowen A; Sweeney EE; Fernandes R
    Front Immunol; 2020; 11():789. PubMed ID: 32425949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
    Kulkosky J; Pomerantz RJ
    Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.